158 related articles for article (PubMed ID: 26440731)
1. Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.
Calcagno A; Cusato J; Marinaro L; Trentini L; Alcantarini C; Mussa M; Simiele M; D'Avolio A; Di Perri G; Bonora S
Pharmacogenomics J; 2016 Nov; 16(6):514-518. PubMed ID: 26440731
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
Punyawudho B; Thammajaruk N; Thongpeang P; Matthews G; Lewin SR; Burger D; Ruxrungtham K; Avihingsanon A
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):947-54. PubMed ID: 26308175
[TBL] [Abstract][Full Text] [Related]
3. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Sungkanuparph S
J Antimicrob Chemother; 2014 Aug; 69(8):2195-201. PubMed ID: 24788661
[TBL] [Abstract][Full Text] [Related]
4. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
[TBL] [Abstract][Full Text] [Related]
5. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Punyawudho B; Pengsuparp T
Antimicrob Agents Chemother; 2015; 59(6):3240-5. PubMed ID: 25801567
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
Calcagno A; Cusato J; Marinaro L; Simiele M; Lucchiari M; Alcantarini C; Tettoni MC; Trentini L; Mengozzi G; D'Avolio A; Di Perri G; Bonora S
AIDS; 2016 Mar; 30(6):915-20. PubMed ID: 26636928
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?
Cusato J; Manca A; Palermiti A; Mula J; Antonucci M; Chiara F; De Nicolò A; Lupia T; Stroffolini G; Boglione L; D'Avolio A
Biomed Pharmacother; 2024 Jun; 175():116678. PubMed ID: 38713940
[TBL] [Abstract][Full Text] [Related]
8. Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting.
Milazzo L; Gervasoni C; Falvella FS; Cattaneo D; Mazzali C; Ronzi P; Binda F; Cheli S; Sollima S; Antinori S
Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):191-196. PubMed ID: 27809359
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Kiser JJ; Aquilante CL; Anderson PL; King TM; Carten ML; Fletcher CV
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):298-303. PubMed ID: 18398970
[TBL] [Abstract][Full Text] [Related]
10. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management.
Gutiérrez F; Fulladosa X; Barril G; Domingo P
AIDS Rev; 2014; 16(4):199-212. PubMed ID: 25350530
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
Nishijima T; Komatsu H; Higasa K; Takano M; Tsuchiya K; Hayashida T; Oka S; Gatanaga H
Clin Infect Dis; 2012 Dec; 55(11):1558-67. PubMed ID: 22955427
[TBL] [Abstract][Full Text] [Related]
12. Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Gvetadze RJ; Curlin ME; Leethochawalit M; Chiamwongpaet S; Cherdtrakulkiat T; Anekvorapong R; Leelawiwat W; Chantharojwong N; McNicholl JM; Paxton LA; Kittimunkong S; Choopanya K;
Clin Infect Dis; 2014 Sep; 59(5):716-24. PubMed ID: 24829212
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients.
Cusato J; Calcagno A; Marinaro L; Avataneo V; DʹAvolio A; Di Perri G; Bonora S
Pharmacogenomics J; 2020 Apr; 20(2):202-212. PubMed ID: 31619748
[TBL] [Abstract][Full Text] [Related]
14. Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.
Wanga V; Venuto C; Morse GD; Acosta EP; Daar ES; Haas DW; Li C; Shepherd BE
Pharmacogenet Genomics; 2015 Sep; 25(9):450-61. PubMed ID: 26148204
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Sukasem C; Punyawudho B
Pharmacogenomics; 2017 Nov; 18(16):1481-1490. PubMed ID: 29061086
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
[TBL] [Abstract][Full Text] [Related]
17. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.
Kearney BP; Sayre JR; Flaherty JF; Chen SS; Kaul S; Cheng AK
J Clin Pharmacol; 2005 Dec; 45(12):1360-7. PubMed ID: 16291710
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2.
Cusato J; Calcagno A; De Nicolò A; Mogyorosi K; D'Avolio A; Di Perri G; Bonora S
Diagn Microbiol Infect Dis; 2019 Jun; 94(2):202-204. PubMed ID: 30922593
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.
Salvaggio SE; Giacomelli A; Falvella FS; Oreni ML; Meraviglia P; Atzori C; Clementi EGI; Galli M; Rusconi S
BMC Infect Dis; 2017 Jun; 17(1):396. PubMed ID: 28583112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
